{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%3A+Hodgkin&page=6", "query": { "condition": "Lymphoma: Hodgkin", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 3812, "total_pages": 382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%3A+Hodgkin&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%3A+Hodgkin&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T22:12:51.775Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003805", "title": "Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bone Marrow Suppression", "Fever, Sweats, and Hot Flashes", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "piperacillin sodium", "type": "DRUG" }, { "name": "piperacillin-tazobactam", "type": "DRUG" }, { "name": "tazobactam sodium", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 859, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-24", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003805" }, { "nct_id": "NCT04906096", "title": "Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Central Nervous System Lymphoma", "Non-Hodgkin Lymphoma of Extranodal Site" ], "interventions": [ { "name": "PAXALISIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lakshmi Nayak, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-06-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906096" }, { "nct_id": "NCT03467373", "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab (G)", "type": "DRUG" }, { "name": "Rituximab (R)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-03-13", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467373" }, { "nct_id": "NCT05938127", "title": "Impact of Respiratory Training in Lymphoma Survivors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hodgkin Lymphoma", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "Inspiratory muscle strength training", "type": "DEVICE" }, { "name": "Sham Inspiratory muscle strength training", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1, "start_date": "2024-09-16", "completion_date": "2024-12-09", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 2, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05938127" }, { "nct_id": "NCT03373305", "title": "Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD30-Positive Neoplastic Cells Present", "Folliculotropic Mycosis Fungoides", "Recurrent Mycosis Fungoides", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-03", "completion_date": "2019-04-26", "has_results": false, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373305" }, { "nct_id": "NCT05165186", "title": "Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dementia", "Dementia Frontotemporal", "Dementia Alzheimers", "Dementia, Mild", "Dementia Moderate", "Dementia Severe", "Caregiver Burnout", "Caregiver Stress Syndrome" ], "interventions": [ { "name": "Video Intervention Arm", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2022-04-13", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2023-10-19", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05165186" }, { "nct_id": "NCT05978141", "title": "A Registry for People With T-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "T-cell Lymphoma", "NK-Cell Lymphoma", "T-cell Prolymphocytic Leukemia", "T-cell Large Granular Lymphocytic Leukemia", "Chronic Lymphoproliferative Disorder of NK Cells", "Aggressive NK-cell Leukemia", "Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)", "Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood", "Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form", "Hydroa Vacciniforme-Like Lymphoproliferative Disorder", "Adult T-cell Leukemia/Lymphoma", "Extranodal NK/T-cell Lymphoma, Nasal Type", "Enteropathy-associated T-cell Lymphoma", "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma", "Intestinal T-Cell Lymphoma, Not Otherwise Specified", "Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract", "Hepatosplenic T-cell Lymphoma", "Subcutaneous Panniculitis-Like T-Cell Lymphoma", "Mycosis Fungoides", "Sezary Syndrome", "Primary Cutaneous Anaplastic Large Cell Lymphoma", "Primary Cutaneous T-cell Lymphoma", "Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma", "Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Anaplastic Large Cell Lymphoma, ALK-negative", "Breast Implant-Associated Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Optional Blood Sample and Nail Sample", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2023-07-27", "completion_date": "2030-07-27", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 26, "location_summary": "Duarte, California • San Diego, California • San Francisco, California + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05978141" }, { "nct_id": "NCT01491841", "title": "IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bendamustine + Rituximab + Pixantrone", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anne Beaven, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2011-11-01", "completion_date": "2017-02-17", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01491841" }, { "nct_id": "NCT05702853", "title": "Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Non Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide injection", "type": "DRUG" }, { "name": "Fludarabine Injection", "type": "DRUG" }, { "name": "CD19-CD34t metabolically programmed CAR transduced T-cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-11-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05702853" }, { "nct_id": "NCT02919670", "title": "A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Enterade", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "Standard Supportive Care", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-10", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2023-03-16", "last_synced_at": "2026-10-11T22:12:51.775Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02919670" } ] }